Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis

J. S. Abramson, C. J. Baker, M. C. Fisher, M. A. Gerber, H. C. Meissner, Dennis L Murray, G. D. Overturf, C. G. Prober, M. B. Rennels, T. N. Saari, L. B. Weiner, R. J. Whitley, G. Peter, L. K. Pickering, N. E. MacDonald, L. Chilton, G. Delage, S. F. Dowell, R. F. Jacobs, M. G. MyersW. A. Orenstein, P. A. Patriarca, E. O. Ledbetter, J. Kim

Research output: Contribution to journalReview article

347 Citations (Scopus)

Abstract

Heptavalent pneumococcal conjugate vaccine (PCV7) is recommended for universal use in children 23 months and younger, to be given concurrently with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months old who have not received previous doses of PCV7, administration of a reduced number of doses is recommended. Two doses of PCV7 are recommended for children 24 to 59 months old at high risk of invasive pneumococcal infection - including children with functional, anatomic, or congenital asplenia; infection with human immunodeficiency virus; and other predisposing conditions - who have not been immunized previously with PCV7. Recommendations have been made for use of 23-valent pneumococcal polysaccharide (23PS) vaccine in high-risk children to expand serotype coverage. High-risk children should be given vaccines at the earliest possible opportunity. Use of antibiotic prophylaxis in children younger than 5 years with functional or anatomic asplenia, including children with sickle cell disease, continues to be recommended. Children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations may discontinue prophylaxis after 5 years of age. The safety and efficacy of PCV7 and 23PS in children 24 months or older at moderate or lower risk of invasive pneumococcal infection remain under investigation. Current US Food and Drug Administration indications are for administration of PCV7 only to children younger than 24 months. Data are insufficient to recommend routine administration of PCV7 for children at moderate risk of pneumococcal invasive infection, including all children 24 to 35 months old, children 36 to 59 months old who attend out-of-home care, and children 36 to 59 months old who are of Native American (American Indian and Alaska Native) or African American descent. However, all children 24 to 59 months old, regardless of whether they are at low or moderate risk, may benefit from the administration of pneumococcal immunizations. Therefore, a single dose of PCV7 or 23PS vaccine may be given to children 24 months or older. The 23PS is an acceptable alternative to PCV7, although an enhanced immune response and probable reduction of nasopharyngeal carriage favor the use of PCV7 whenever possible.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalPediatrics
Volume106
Issue number2 I
DOIs
StatePublished - Jan 1 2000

Fingerprint

Pneumococcal Infections
Conjugate Vaccines
Pneumococcal Vaccines
Antibiotic Prophylaxis
North American Indians
Heptavalent Pneumococcal Conjugate Vaccine
Polysaccharides
Immunization
Vaccines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Policy statement : Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. / Abramson, J. S.; Baker, C. J.; Fisher, M. C.; Gerber, M. A.; Meissner, H. C.; Murray, Dennis L; Overturf, G. D.; Prober, C. G.; Rennels, M. B.; Saari, T. N.; Weiner, L. B.; Whitley, R. J.; Peter, G.; Pickering, L. K.; MacDonald, N. E.; Chilton, L.; Delage, G.; Dowell, S. F.; Jacobs, R. F.; Myers, M. G.; Orenstein, W. A.; Patriarca, P. A.; Ledbetter, E. O.; Kim, J.

In: Pediatrics, Vol. 106, No. 2 I, 01.01.2000, p. 362-366.

Research output: Contribution to journalReview article

Abramson, JS, Baker, CJ, Fisher, MC, Gerber, MA, Meissner, HC, Murray, DL, Overturf, GD, Prober, CG, Rennels, MB, Saari, TN, Weiner, LB, Whitley, RJ, Peter, G, Pickering, LK, MacDonald, NE, Chilton, L, Delage, G, Dowell, SF, Jacobs, RF, Myers, MG, Orenstein, WA, Patriarca, PA, Ledbetter, EO & Kim, J 2000, 'Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis', Pediatrics, vol. 106, no. 2 I, pp. 362-366. https://doi.org/10.1542/peds.106.2.362
Abramson, J. S. ; Baker, C. J. ; Fisher, M. C. ; Gerber, M. A. ; Meissner, H. C. ; Murray, Dennis L ; Overturf, G. D. ; Prober, C. G. ; Rennels, M. B. ; Saari, T. N. ; Weiner, L. B. ; Whitley, R. J. ; Peter, G. ; Pickering, L. K. ; MacDonald, N. E. ; Chilton, L. ; Delage, G. ; Dowell, S. F. ; Jacobs, R. F. ; Myers, M. G. ; Orenstein, W. A. ; Patriarca, P. A. ; Ledbetter, E. O. ; Kim, J. / Policy statement : Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. In: Pediatrics. 2000 ; Vol. 106, No. 2 I. pp. 362-366.
@article{960d326f96844cec9e6deca410444134,
title = "Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis",
abstract = "Heptavalent pneumococcal conjugate vaccine (PCV7) is recommended for universal use in children 23 months and younger, to be given concurrently with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months old who have not received previous doses of PCV7, administration of a reduced number of doses is recommended. Two doses of PCV7 are recommended for children 24 to 59 months old at high risk of invasive pneumococcal infection - including children with functional, anatomic, or congenital asplenia; infection with human immunodeficiency virus; and other predisposing conditions - who have not been immunized previously with PCV7. Recommendations have been made for use of 23-valent pneumococcal polysaccharide (23PS) vaccine in high-risk children to expand serotype coverage. High-risk children should be given vaccines at the earliest possible opportunity. Use of antibiotic prophylaxis in children younger than 5 years with functional or anatomic asplenia, including children with sickle cell disease, continues to be recommended. Children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations may discontinue prophylaxis after 5 years of age. The safety and efficacy of PCV7 and 23PS in children 24 months or older at moderate or lower risk of invasive pneumococcal infection remain under investigation. Current US Food and Drug Administration indications are for administration of PCV7 only to children younger than 24 months. Data are insufficient to recommend routine administration of PCV7 for children at moderate risk of pneumococcal invasive infection, including all children 24 to 35 months old, children 36 to 59 months old who attend out-of-home care, and children 36 to 59 months old who are of Native American (American Indian and Alaska Native) or African American descent. However, all children 24 to 59 months old, regardless of whether they are at low or moderate risk, may benefit from the administration of pneumococcal immunizations. Therefore, a single dose of PCV7 or 23PS vaccine may be given to children 24 months or older. The 23PS is an acceptable alternative to PCV7, although an enhanced immune response and probable reduction of nasopharyngeal carriage favor the use of PCV7 whenever possible.",
author = "Abramson, {J. S.} and Baker, {C. J.} and Fisher, {M. C.} and Gerber, {M. A.} and Meissner, {H. C.} and Murray, {Dennis L} and Overturf, {G. D.} and Prober, {C. G.} and Rennels, {M. B.} and Saari, {T. N.} and Weiner, {L. B.} and Whitley, {R. J.} and G. Peter and Pickering, {L. K.} and MacDonald, {N. E.} and L. Chilton and G. Delage and Dowell, {S. F.} and Jacobs, {R. F.} and Myers, {M. G.} and Orenstein, {W. A.} and Patriarca, {P. A.} and Ledbetter, {E. O.} and J. Kim",
year = "2000",
month = "1",
day = "1",
doi = "10.1542/peds.106.2.362",
language = "English (US)",
volume = "106",
pages = "362--366",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2 I",

}

TY - JOUR

T1 - Policy statement

T2 - Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis

AU - Abramson, J. S.

AU - Baker, C. J.

AU - Fisher, M. C.

AU - Gerber, M. A.

AU - Meissner, H. C.

AU - Murray, Dennis L

AU - Overturf, G. D.

AU - Prober, C. G.

AU - Rennels, M. B.

AU - Saari, T. N.

AU - Weiner, L. B.

AU - Whitley, R. J.

AU - Peter, G.

AU - Pickering, L. K.

AU - MacDonald, N. E.

AU - Chilton, L.

AU - Delage, G.

AU - Dowell, S. F.

AU - Jacobs, R. F.

AU - Myers, M. G.

AU - Orenstein, W. A.

AU - Patriarca, P. A.

AU - Ledbetter, E. O.

AU - Kim, J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Heptavalent pneumococcal conjugate vaccine (PCV7) is recommended for universal use in children 23 months and younger, to be given concurrently with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months old who have not received previous doses of PCV7, administration of a reduced number of doses is recommended. Two doses of PCV7 are recommended for children 24 to 59 months old at high risk of invasive pneumococcal infection - including children with functional, anatomic, or congenital asplenia; infection with human immunodeficiency virus; and other predisposing conditions - who have not been immunized previously with PCV7. Recommendations have been made for use of 23-valent pneumococcal polysaccharide (23PS) vaccine in high-risk children to expand serotype coverage. High-risk children should be given vaccines at the earliest possible opportunity. Use of antibiotic prophylaxis in children younger than 5 years with functional or anatomic asplenia, including children with sickle cell disease, continues to be recommended. Children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations may discontinue prophylaxis after 5 years of age. The safety and efficacy of PCV7 and 23PS in children 24 months or older at moderate or lower risk of invasive pneumococcal infection remain under investigation. Current US Food and Drug Administration indications are for administration of PCV7 only to children younger than 24 months. Data are insufficient to recommend routine administration of PCV7 for children at moderate risk of pneumococcal invasive infection, including all children 24 to 35 months old, children 36 to 59 months old who attend out-of-home care, and children 36 to 59 months old who are of Native American (American Indian and Alaska Native) or African American descent. However, all children 24 to 59 months old, regardless of whether they are at low or moderate risk, may benefit from the administration of pneumococcal immunizations. Therefore, a single dose of PCV7 or 23PS vaccine may be given to children 24 months or older. The 23PS is an acceptable alternative to PCV7, although an enhanced immune response and probable reduction of nasopharyngeal carriage favor the use of PCV7 whenever possible.

AB - Heptavalent pneumococcal conjugate vaccine (PCV7) is recommended for universal use in children 23 months and younger, to be given concurrently with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months old who have not received previous doses of PCV7, administration of a reduced number of doses is recommended. Two doses of PCV7 are recommended for children 24 to 59 months old at high risk of invasive pneumococcal infection - including children with functional, anatomic, or congenital asplenia; infection with human immunodeficiency virus; and other predisposing conditions - who have not been immunized previously with PCV7. Recommendations have been made for use of 23-valent pneumococcal polysaccharide (23PS) vaccine in high-risk children to expand serotype coverage. High-risk children should be given vaccines at the earliest possible opportunity. Use of antibiotic prophylaxis in children younger than 5 years with functional or anatomic asplenia, including children with sickle cell disease, continues to be recommended. Children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations may discontinue prophylaxis after 5 years of age. The safety and efficacy of PCV7 and 23PS in children 24 months or older at moderate or lower risk of invasive pneumococcal infection remain under investigation. Current US Food and Drug Administration indications are for administration of PCV7 only to children younger than 24 months. Data are insufficient to recommend routine administration of PCV7 for children at moderate risk of pneumococcal invasive infection, including all children 24 to 35 months old, children 36 to 59 months old who attend out-of-home care, and children 36 to 59 months old who are of Native American (American Indian and Alaska Native) or African American descent. However, all children 24 to 59 months old, regardless of whether they are at low or moderate risk, may benefit from the administration of pneumococcal immunizations. Therefore, a single dose of PCV7 or 23PS vaccine may be given to children 24 months or older. The 23PS is an acceptable alternative to PCV7, although an enhanced immune response and probable reduction of nasopharyngeal carriage favor the use of PCV7 whenever possible.

UR - http://www.scopus.com/inward/record.url?scp=0033869176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869176&partnerID=8YFLogxK

U2 - 10.1542/peds.106.2.362

DO - 10.1542/peds.106.2.362

M3 - Review article

C2 - 10920169

AN - SCOPUS:0033869176

VL - 106

SP - 362

EP - 366

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2 I

ER -